Discover trends, market shifts, and competitive outlooks for the polymyositis industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Current and Projected Market Size of the Polymyositis Market Through 2034?

The market for polymyositis has experienced robust growth in the recent past. Starting from a $1.65 billion valuation in 2024, it is expected to reach $1.75 billion by 2025, marking a compound annual growth rate (CAGR) of 6.4%. This upward trend during the historic period was likely due to improved access in emerging regions, a rise in prednisone application, an increase in acceptance of methotrexate for symptom management, enlargement in the usage of TNF inhibitors, and a surge in antibody testing application.

The market size for polymyositis is anticipated to experience robust expansion in the upcoming years, with a projection to reach $2.23 billion by 2029, along with a compound annual growth rate (CAGR) of 6.2%. The anticipated growth within this forecast period can be credited to the expansion of telemedicine, increased use of remote patient monitoring, a surge in the employment of immunosuppressants, growth in stem cell therapy applications, and an upsurge in the use of biosimilars. Key trends expected to emerge during this forecast period comprise the incorporation of artificial intelligence in drug discovery, advancements in specific therapeutics, development of new immunomodulators, amplified research in the regenerative medicine sphere, and the assimilation of substantial data.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Polymyositis Market?

The growing occurrence of autoimmune diseases is anticipated to spur the expansion of the polymyositis market. Autoimmune diseases are medical situations in which the immune system erroneously attacks healthy cells, tissues, or organs in the body, resulting in inflammation and harm. The escalating rate of autoimmune diseases hinges on certain genetic variants that overstimulate immune responses, rendering individuals vulnerable to mistakenly attacking their own tissues. Hence, this genetic predisposition, alongside environmentally instigated factors like infections, stress, and lifestyle aspects, play a part in the escalating incidents of autoimmune conditions. Polymyositis acts as a lens to comprehend autoimmune diseases by showcasing how immune system malfunction leads to muscular inflammation, thus presenting an understanding of root mechanisms and potential remedies for related conditions. For example, in November 2024, Versorgungsatlas.de, based in Germany, stated that in 2022, out of 73,241,305 insured citizens, 6,304,340 were diagnosed with at least one autoimmune disease, indicating a raw prevalence rate of 8.61%. Thus, the increasing prevalence of autoimmune diseases propels the Polymyositis market. A surge in demand for oral drugs is projected to drive the growth of the polymyositis market. Oral drugs, as consumables—tablets, capsules or liquids—are taken by mouth and digested through the alimentary canal. This heightened demand is linked to their ease of use, simple administration and patient choice for non-intrusive treatments over injections or other means. Polymyositis leverages oral drugs to lessen muscular inflammation, modify immune responses and improve muscle function, thereby alleviating symptoms and preventing further progress of the disease. As an example, the Centers for Disease Control and Prevention in the US reported in October 2022 that disbursement of oral antivirals witnessed an increase of 57% from 643 per 100,000 people from April 24 to May 21, 2022, to 1,012 per 100,000 during July 31 and August 28, 2022. Consequently, the escalating demand for oral drugs is fostering the expansion of the polymyositis market.

Which Key Market Segments Comprise the Polymyositis Market and Drive Its Revenue Growth?

The polymyositis market covered in this report is segmented –

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes

2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)

3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies

4) By Distribution Channel: Offline, Online

5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegmentss:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis

2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis

3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy

4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22104&type=smp

Which Areas Are Leading Regions in the Polymyositis Market Expansion Across the Globe?

North America was the largest region in the polymyositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Strategic Trends Steering thePolymyositis Market Direction?

Key players within the polymyositis market are focusing on the development of novel treatments, such as stem cell therapy, to heighten treatment effectiveness and slow the progression of the disease. The basis of the stem cell therapy is the usage of stem cells derived from the umbilical cord as a means of regenerative treatment. These cells possess robust immunomodulatory and anti-inflammatory characteristics, implying that they could be useful in treating autoimmune disorders such as polymyositis. As an example, RESTEM, an American clinical-stage biotech firm, was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for its program which uses umbilical cord outer lining stem cells (ULSCs) in December 2024. This program is helping in the treatment of polymyositis and Dermatomyositis by modulating the immune system and reducing muscle inflammation. The potential to reduce steroid dependence was evidenced by the promising safety and efficacy results of early trials of the treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

How Is the Polymyositis Market Conceptually Defined?

Polymyositis is a chronic inflammatory myopathy characterized by progressive muscle weakness, primarily affecting the skeletal muscles. It results from an autoimmune response where the body’s immune system mistakenly attacks muscle fibers, leading to inflammation, degeneration, and weakness.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22104

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model